XenoPort to Present at the RBC Capital Markets' Healthcare Conference
February 23 2012 - 1:00PM
Business Wire
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will
provide access via the World Wide Web to its presentation at the
RBC Capital Markets' Healthcare Conference. The live presentation
will occur at 11:00 a.m. Pacific Time (2:00 p.m. Eastern Time) on
Wednesday, February 29, 2012. A replay of the presentation will
also be available.
To access the live presentation via the Web, please go to
www.XenoPort.com. Please connect to the Website at least 15 minutes
prior to the live presentation to ensure adequate time for any
software downloads that may be necessary to listen to the
Webcast.
A replay of the Webcast can be accessed for a minimum of one
week and will be available approximately 24 hours after the live
presentation.
About XenoPort
XenoPort is a biopharmaceutical company focused on developing
and commercializing a portfolio of internally discovered product
candidates for the potential treatment of neurological disorders.
Horizant® (gabapentin enacarbil) Extended-Release Tablets is
XenoPort’s first U.S. Food and Drug Administration-approved
product. GlaxoSmithKline currently holds commercialization rights
and certain development rights for gabapentin enacarbil in the
United States. Regnite® (gabapentin enacarbil) is approved for the
treatment of moderate-to-severe primary restless legs syndrome in
Japan. Astellas Pharma Inc. holds all development and
commercialization rights for Regnite in Japan and gabapentin
enacarbil in five Asian countries. XenoPort holds all other
world-wide rights and has co-promotion and certain development
rights to gabapentin enacarbil in the United States. XenoPort’s
pipeline of product candidates includes potential treatments for
patients with postherpetic neuralgia, spasticity and Parkinson’s
disease.
To learn more about XenoPort, please visit the Website at
www.XenoPort.com.
XENOPORT is a registered trademark of XenoPort, Inc.
Horizant is a registered trademark of GlaxoSmithKline.
Regnite is a registered trademark of Astellas Pharma Inc.
XNPT2G
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From Sep 2023 to Sep 2024